Invention Grant
- Patent Title: IL-2 superagonists in combination with anti-PD-1 antibodies
-
Application No.: US16012733Application Date: 2018-06-19
-
Publication No.: US11542312B2Publication Date: 2023-01-03
- Inventor: Fahar Merchant , Shafique Fidai
- Applicant: Medicenna Therapeutics, Inc.
- Applicant Address: CA Toronto
- Assignee: Medicenna Therapeutics, Inc.
- Current Assignee: Medicenna Therapeutics, Inc.
- Current Assignee Address: CA Toronto
- Agency: Morgan, Lewis & Bockius LLP
- Main IPC: A61K38/20
- IPC: A61K38/20 ; A61K39/395 ; C07K14/55 ; C07K16/28 ; C07K16/30 ; C07K19/00 ; C07K14/76 ; A61P35/00 ; A61K38/17 ; A61K39/00 ; C12N7/00 ; A61K35/76
Abstract:
Human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor as compared to wild-type IL-2 for use in combination therapies with anti-PD-1 antibodies for the treatment of cancer. Also provided are pharmaceutical compositions that include such anti-PD-1 antibodies and the disclosed IL-2 muteins.
Public/Granted literature
- US20190062395A1 IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES Public/Granted day:2019-02-28
Information query
IPC分类:
